Your browser doesn't support javascript.
loading
Posaconazole versus voriconazole for primary treatment of invasive aspergillosis: a phase 3, randomised, controlled, non-inferiority trial.
Maertens, Johan A; Rahav, Galia; Lee, Dong-Gun; Ponce-de-León, Alfredo; Ramírez Sánchez, Isabel Cristina; Klimko, Nikolay; Sonet, Anne; Haider, Shariq; Diego Vélez, Juan; Raad, Issam; Koh, Liang-Piu; Karthaus, Meinolf; Zhou, Jianying; Ben-Ami, Ronen; Motyl, Mary R; Han, Seongah; Grandhi, Anjana; Waskin, Hetty.
Afiliação
  • Maertens JA; Department of Microbiology, Immunology, and Transplantation, KU Leuven, Leuven, Belgium; Department of Hematology, University Hospitals Leuven, Leuven, Belgium. Electronic address: johan.maertens@uzleuven.be.
  • Rahav G; Sheba Medical Center, Tel-Hashomer, Ramat Gan, Israel; Sackler School of Medicine, Tel Aviv University, Ramat Gan, Israel.
  • Lee DG; Division of Infectious Diseases, Department of Internal Medicine, The Catholic University of Korea, Seoul, South Korea.
  • Ponce-de-León A; Instituto Nacional de Ciencias Médicas y Nutrición Salvador Zubirán, Mexico City, México.
  • Ramírez Sánchez IC; Hospital Pablo Tobón Uribe, Universidad de Antioquia, Medellín, Colombia.
  • Klimko N; Department of Clinical Mycology, Allergy and Immunology, North Western State Medical University, St Petersburg, Russia.
  • Sonet A; CHU UCL Namur, Université Catholique de Louvain, Yvoir, Belgium.
  • Haider S; Juravinski Hospital and Cancer Center, McMaster University, Hamilton, ON, Canada.
  • Diego Vélez J; Fundación Valle del Lili, Cali, Colombia.
  • Raad I; The University of Texas MD Anderson Cancer Center, Houston, TX, USA.
  • Koh LP; National University Cancer Institute, National University Health System, Singapore.
  • Karthaus M; Klinikum Neuperlach, Munich, Germany.
  • Zhou J; Department of Respiratory Diseases, The First Affiliated Hospital, Zhejiang University School of Medicine, Hangzhou, China.
  • Ben-Ami R; Tel Aviv Sourasky Medical Center and Sackler Faculty of Medicine, Tel Aviv University, Tel Aviv, Israel.
  • Motyl MR; Department of Clinical Microbiology, Merck & Co, Inc, Kenilworth, NJ, USA.
  • Han S; Department of Diabetes/NASH, Merck & Co, Inc, Kenilworth, NJ, USA.
  • Grandhi A; Department of Biostatistics, Merck & Co, Inc, Kenilworth, NJ, USA.
  • Waskin H; Department of Infectious Disease, Merck & Co, Inc, Kenilworth, NJ, USA.
Lancet ; 397(10273): 499-509, 2021 02 06.
Article em En | MEDLINE | ID: mdl-33549194
Assuntos
Texto completo
Imprimir
XML
PubMed Links
Buscar no Google

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Assunto principal: Triazóis / Aspergilose Pulmonar Invasiva / Voriconazol / Antifúngicos Tipo de estudo: Clinical_trials / Observational_studies Limite: Adolescent / Adult / Female / Humans / Male / Middle aged Idioma: En Revista: Lancet Ano de publicação: 2021 Tipo de documento: Article
Texto completo
Imprimir
XML
PubMed Links
Buscar no Google

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Assunto principal: Triazóis / Aspergilose Pulmonar Invasiva / Voriconazol / Antifúngicos Tipo de estudo: Clinical_trials / Observational_studies Limite: Adolescent / Adult / Female / Humans / Male / Middle aged Idioma: En Revista: Lancet Ano de publicação: 2021 Tipo de documento: Article